List of Excipients in Branded Drug AGAMREE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Purna Pharmaceuticals NV	AGAMREE	vamorolone	62450-003	CITRIC ACID MONOHYDRATE	2040-07-16
Purna Pharmaceuticals NV	AGAMREE	vamorolone	62450-003	GLYCERIN	2040-07-16
Purna Pharmaceuticals NV	AGAMREE	vamorolone	62450-003	SODIUM BENZOATE	2040-07-16
Purna Pharmaceuticals NV	AGAMREE	vamorolone	62450-003	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS	2040-07-16

AGAMREE Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

AGAMREE, Santhera Pharmaceuticals’ vamorolone oral suspension, uses a pediatric liquid excipient system designed for dose flexibility, suspension stability, palatability, and administration by oral syringe. The commercial opportunity is strongest in differentiated pediatric delivery, global supply of functional excipients, improved taste and stability, and generic-ready formulation development.

What excipients are used in AGAMREE oral suspension?

AGAMREE is a 40 mg/mL oral suspension. The FDA-approved formulation contains the following inactive ingredients:

Excipient	Likely formulation function
Glycerin	Humectant, viscosity modifier, mouthfeel enhancer
Microcrystalline cellulose	Suspending agent and structured vehicle
Carboxymethylcellulose sodium	Viscosity control and particle suspension
Poloxamer 188	Wetting agent and dispersion aid
Sodium citrate dihydrate	Buffering and pH control
Citric acid monohydrate	Acidifying agent and buffer component
Sucralose	High-intensity sweetener
Cherry flavor	Taste masking
Purified water	Liquid vehicle

The composition is disclosed in the AGAMREE prescribing information approved by the U.S. Food and Drug Administration (FDA). The label directs shaking before use and administration with a calibrated oral syringe, which confirms that dose uniformity and redispersion are central quality attributes.[1]

How the AGAMREE vehicle works

The formulation uses a cellulose-based suspension system rather than a simple solution. Vamorolone has limited suitability for a conventional aqueous solution at the marketed concentration, making particle wetting, suspension uniformity, and sedimentation control important.

Microcrystalline cellulose and sodium carboxymethylcellulose provide a structured vehicle. The combination can reduce rapid settling while allowing the suspension to redisperse after shaking. Poloxamer 188 supports wetting of drug particles and can help reduce agglomeration. Glycerin contributes viscosity and improves mouthfeel.

The citrate system controls pH. Sucralose and cherry flavor address the taste burden associated with an orally administered corticosteroid. These choices are commercially relevant because AGAMREE is used in children as young as two years old and is administered chronically for Duchenne muscular dystrophy (DMD).[1]

What is the commercial role of AGAMREE’s excipient strategy?

The excipient system supports four commercial requirements:

1. Pediatric acceptability.
2. Accurate weight-based dosing.
3. Stable distribution as a ready-to-use liquid.
4. Differentiation from conventional corticosteroid tablets and compounded liquids.

AGAMREE is dosed once daily according to body weight, with the label specifying a recommended dosage of 6 mg/kg/day and a maximum daily dose of 300 mg.[1] A 40 mg/mL suspension allows dose volumes to be adjusted as a child grows without changing the dosage form.

This creates a practical advantage over fixed-strength tablets. It also reduces dependence on pharmacy compounding, where concentration, microbial quality, stability, and dose uniformity may vary.

Why dose flexibility matters in DMD

DMD treatment is long term, and patients experience rapid changes in body weight during childhood and adolescence. A liquid product permits incremental dose adjustments using an oral syringe. This can support adherence and reduce the need to split or combine tablets.

The commercial value of the excipient system is therefore linked to the delivery format, not only to the active pharmaceutical ingredient. A generic competitor would need to reproduce or closely match the suspension’s physical performance, dosing accuracy, palatability, and stability.

Which excipients create the strongest formulation opportunities?

Suspending-agent systems

Microcrystalline cellulose and sodium carboxymethylcellulose are widely used pharmaceutical excipients, but their performance depends on grade, particle size, substitution level, hydration behavior, and processing conditions.

Potential supplier opportunities include:

• Low-bioburden grades for pediatric liquids.
• Consistent hydration and viscosity profiles.
• Improved redispersion after prolonged storage.
• Lower sedimentation without excessive syringe resistance.
• Excipient systems optimized for high-drug-load suspensions.

A supplier that can offer a validated, compendial suspension platform may compete for AGAMREE-related supply without owning the active pharmaceutical ingredient.

Wetting and dispersion systems

Poloxamer 188 is a functional excipient with applications in wetting, dispersion, and particle stabilization. The opportunity is strongest where a supplier can demonstrate:

• Low peroxide and impurity levels.
• Consistent molecular-weight distribution.
• Reliable performance across manufacturing lots.
• Compatibility with the drug substance and flavor system.
• Acceptable extractables and leachables profiles.

For a chronic pediatric product, tighter impurity control can become a meaningful procurement criterion even when the excipient is not novel.

Flavor and sweetener systems

Cherry flavor and sucralose provide an obvious platform for taste-masking innovation. Commercial opportunities include:

• Lower-sugar or sugar-free pediatric suspensions.
• Flavor variants for different markets.
• Reduced aftertaste.
• Better masking of bitterness at higher concentrations.
• Flavor systems with improved stability during long-term storage.

Flavor changes may require regulatory bridging, stability work, and renewed palatability assessment. They also may create new intellectual-property positions if combined with a specific suspension matrix or drug-particle treatment.

Preservative-free systems

The marketed AGAMREE label does not identify a conventional antimicrobial preservative among the listed inactive ingredients.[1] That creates a potential competitive advantage for pediatric use, particularly where parents and clinicians prefer to limit unnecessary preservatives.

A preservative-free strategy increases the importance of:

• Manufacturing controls.
• Container-closure integrity.
• Microbial limits.
• In-use stability.
• Dose-delivery hygiene.
• Multidose packaging design.

A competing product could pursue a preservative-containing format for lower manufacturing cost, but the change would alter the product’s pediatric positioning and could affect tolerability perceptions.

What formulation patents could protect AGAMREE or a competing product?

Formulation patent value would likely concentrate on the following technical features:

• Vamorolone particle-size distribution.
• Specific suspension-agent ratios.
• Redispersibility after storage.
• Viscosity and sedimentation behavior.
• pH ranges.
• Flavor and sweetener combinations.
• Preservative-free multidose packaging.
• Stability under accelerated and long-term conditions.
• Oral syringe dosing accuracy.
• Manufacturing processes for incorporating vamorolone into the suspension.

A patent directed only to a conventional combination of glycerin, cellulose derivatives, citrate buffer, poloxamer, sucralose, and flavor could face validity and obviousness scrutiny because each component is well known. Stronger claims would generally require a measurable technical result, such as improved stability, reduced sedimentation, improved dose uniformity, or a defined performance range.

The marketed excipient list does not, by itself, establish the scope of Santhera’s patent claims. Patent protection must be evaluated claim by claim against issued patents, pending applications, terminal disclaimers, prosecution history, and Orange Book listings.

When does AGAMREE lose regulatory exclusivity?

AGAMREE received FDA approval on October 26, 2023, for the treatment of DMD in patients at least two years old.[2] Its principal U.S. regulatory protections are summarized below.

Protection	Approximate timing	Commercial effect
New chemical entity exclusivity	October 2028	Blocks submission of an ANDA relying on the drug’s approval during the five-year period, subject to statutory exceptions
Orphan-drug exclusivity	October 2030	Blocks approval of the same drug for the same orphan indication, subject to statutory exceptions
Pediatric exclusivity	Potential additional six months	Available only if FDA grants it after completion of requested pediatric studies
Patent protection	Patent-specific	Depends on issued claims, expiration dates, and listed patents

FDA approved AGAMREE under NDA 215239.[1] Because vamorolone is a small molecule, the principal follow-on pathway is an abbreviated new drug application, not a biosimilar application.

Can generic companies file Paragraph IV challenges against AGAMREE?

Yes. A generic manufacturer could file an ANDA with a Paragraph IV certification against any relevant listed patent. The timing and practical value of that challenge would depend on the patents listed in the FDA Orange Book and the period of regulatory exclusivity remaining when the ANDA is filed.

Potential generic strategies include:

• A Paragraph IV challenge to formulation patents.
• A non-infringement position based on a different excipient ratio.
• An invalidity challenge against obviousness or written-description claims.
• A different flavor system.
• A different suspending-agent combination.
• A drug product with equivalent pharmacokinetics but nonidentical inactive ingredients.

A generic suspension would need to demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements. For orally administered suspensions, inactive ingredients can differ from the reference product, but the differences cannot compromise safety, efficacy, performance, or bioequivalence.

What generic launch scenarios exist?

Scenario	Timing profile	Competitive consequence
No successful patent challenge	After key regulatory and patent barriers expire	Santhera retains substantial protection
Paragraph IV litigation with settlement	Potentially before patent expiry	Entry date depends on settlement terms
Successful Paragraph IV challenge	Potentially before patent expiry	Early generic launch risk
Authorized generic	Controlled by the brand or licensee	Price competition before independent generic entry
Alternative indication	Subject to patent and exclusivity limits	May create a separate regulatory pathway

An ANDA applicant that receives a Paragraph IV certification can trigger patent litigation if the patent owner files suit within the statutory period. A 30-month stay may delay FDA approval while litigation proceeds, although the stay is subject to statutory limitations and court outcomes.

What is the Orange Book status of AGAMREE?

FDA’s Orange Book is the controlling source for listed patents and exclusivity codes. The regulatory exclusivity is clear from the approval date, but a definitive Orange Book patent analysis requires the current product-specific listing and any updates after the initial approval.

The commercial significance of the Orange Book record is high because listed patents can determine:

• Whether an ANDA applicant must make a Paragraph IV certification.
• Whether patent litigation is likely.
• Whether a 30-month stay may apply.
• Whether an authorized generic strategy has value.
• How much of the market may remain protected after NCE exclusivity ends.

A formulation patent that is not listed in the Orange Book may still create litigation exposure under other legal theories, but it would not necessarily create the same ANDA certification dynamics as a properly listed drug-product or method-of-use patent.

How strong is AGAMREE’s excipient-based patent estate?

The commercial strength of an excipient strategy depends on claim breadth and technical evidence.

Patent characteristic	Strength assessment
Broad claim to known excipients without performance limits	Vulnerable to obviousness challenges
Defined excipient ratios with stability data	Stronger
Claims tied to dose uniformity or redispersibility	Potentially valuable
Claims covering a specific particle-size range	Strong if linked to unexpected performance
Flavor-only claims	Usually narrow
Container-closure and in-use stability claims	Useful for product differentiation
Manufacturing-process claims	Can create supply-chain barriers but may be difficult to detect in finished product

The strongest commercial position would combine drug-substance patents, formulation patents, method-of-use patents, regulatory exclusivity, and manufacturing know-how. Excipient patents alone are unlikely to provide the full protection needed for a high-value chronic pediatric product.

What licensing and supply opportunities exist?

Santhera entered into a U.S. commercialization agreement with Catalyst Pharmaceuticals for AGAMREE. Catalyst is responsible for commercialization in the United States and Puerto Rico under the agreement announced by the companies.[3]

The excipient supply chain creates separate licensing and contracting opportunities:

• Preferred-supplier agreements for cellulose derivatives.
• Regional supply contracts for poloxamer 188.
• Flavor licenses for cherry taste systems.
• Contract development and manufacturing of suspension concentrates.
• Packaging agreements for multidose bottles and oral syringes.
• Technology licenses for preservative-free liquid formulations.
• Co-development of lower-concentration or reconstituted products.

Excipient vendors can capture value without licensing vamorolone if their contribution is a validated platform, process, or performance specification rather than an active-ingredient right.

How does AGAMREE compare with prednisone and deflazacort?

Attribute	AGAMREE	Prednisone	Deflazacort
Active ingredient	Vamorolone	Prednisone	Deflazacort
Primary DMD dosage form	Ready-to-use oral suspension	Tablets and liquid products vary by market	Tablets and oral suspension products vary by market
Pediatric dose flexibility	High	Depends on product	Depends on product
Formulation differentiation	Suspension matrix, flavor, syringe delivery	More mature generic market	Established corticosteroid market
Regulatory status in DMD	FDA-approved for patients age 2 and older	Used clinically, but product-specific approvals differ	FDA-approved for DMD
Generic pressure	Limited before exclusivity and patent barriers expire	High	Increasing
Excipient opportunity	High because of branded liquid platform	Lower for standard tablets	Moderate for liquid formulations

AGAMREE’s commercial differentiation rests on its vamorolone pharmacology and its pediatric liquid presentation. Prednisone and deflazacort have broader historical use and stronger generic availability, but their formulation economics and tolerability profiles differ.

What commercial opportunities exist for excipient manufacturers?

The most actionable opportunities are:

1. Supply of high-consistency cellulose suspending agents.
2. Pediatric flavor systems with stronger bitterness masking.
3. Preservative-free multidose packaging.
4. Oral syringes calibrated for weight-based dosing.
5. Lower-viscosity vehicles that improve syringeability.
6. Excipient systems supporting longer in-use stability.
7. Alternative formulations for global markets with different temperature and transport conditions.
8. Generic-ready Q1/Q2 suspension platforms.
9. Analytical methods for sedimentation, redispersibility, and dose uniformity.
10. Manufacturing-process licenses for high-drug-load suspensions.

A competing company could also pursue a ready-to-use liquid with a different concentration, a powder for reconstitution, or a tablet formulation. Each approach would face different regulatory, palatability, manufacturing, and patent risks.

Key Takeaways

• AGAMREE is a 40 mg/mL vamorolone oral suspension for DMD patients at least two years old.
• Its excipient system combines glycerin, cellulose suspending agents, poloxamer 188, citrate buffer, sucralose, cherry flavor, and purified water.
• The core technical challenges are suspension stability, redispersibility, dose uniformity, palatability, and preservative-free microbial control.
• The most attractive excipient opportunities involve pediatric taste masking, cellulose-based suspension platforms, low-impurity poloxamer 188, and multidose packaging.
• FDA approval occurred on October 26, 2023. NCE exclusivity is expected to run to October 2028, while orphan exclusivity is expected to run to October 2030, subject to statutory conditions.
• Generic companies may pursue Paragraph IV challenges against listed patents, but a precise launch-risk assessment depends on the current Orange Book record and patent claims.
• AGAMREE is exposed primarily to generic competition, not biosimilar competition.
• Formulation patents are strongest when tied to measurable improvements in stability, dose uniformity, redispersibility, or manufacturing performance.

FAQs

Is AGAMREE a solution or a suspension?

AGAMREE is an oral suspension. Patients must shake the bottle before each dose to redistribute vamorolone particles.

Does AGAMREE contain a preservative?

The FDA-listed inactive ingredients do not identify a conventional antimicrobial preservative. Microbial control therefore depends heavily on manufacturing, packaging, storage, and in-use controls.[1]

Which excipient is most important for AGAMREE suspension stability?

Microcrystalline cellulose and sodium carboxymethylcellulose are the principal structural excipients. Their grade, ratio, hydration, and viscosity characteristics are likely to affect settling and redispersion.

Can a generic AGAMREE use different excipients?

Yes, provided the proposed formulation meets FDA requirements for pharmaceutical equivalence, performance, safety, and bioequivalence. A different excipient system could also reduce direct formulation-patent overlap.

Is AGAMREE subject to biosimilar competition?

No. Vamorolone is a small-molecule drug. Follow-on products would generally use the ANDA generic pathway rather than the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2023). AGAMREE (vamorolone) oral suspension, prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023, October 26). FDA approves new treatment for Duchenne muscular dystrophy. FDA.

3. Catalyst Pharmaceuticals, Inc. (2024). Catalyst Pharmaceuticals and Santhera Pharmaceuticals announce U.S. commercialization agreement for AGAMREE. Catalyst Pharmaceuticals.